Prostate cancer drugs took center stage at this year’s meeting of the American Society of Clinical Oncology, with Johnson & Johnson Zytiga and Medivation’s Enzalutamide generating excitement. David Miller, president and CEO of Biotech Stock Research, says the news is not all bad for Dendreon, which faces new competition for its prostate cancer Provenge. We spoke to Miller about the recently concluded ASCO meeting, who the big winners were this year, and why Big Pharma has come to dominate the headlines at the conference.